{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-009490","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.811826+00:00","generated_at":"2026-05-25T17:31:33.899933+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"X4 Pharmaceuticals gets second Nasdaq compliance period until Aug 11, 2025 for bid price rule","bullets":["Closing bid price of XFOR common stock below $1 for 32 consecutive business days as of Aug 13, 2024.","Initial 180-day compliance period ended Feb 10, 2025; Nasdaq granted additional 180 days to Aug 11, 2025.","Company may effect a reverse stock split to regain compliance if necessary.","Failure to comply by Aug 11, 2025 may lead to delisting and an appeal process."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-009490","json":"https://secwatch.observer/filing/0001628280-25-009490.json","markdown":"https://secwatch.observer/filing/0001628280-25-009490.md","text":"https://secwatch.observer/filing/0001628280-25-009490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025009490/0001628280-25-009490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025009490/xfor-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:31:33.899933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}